Meeting
2018 Gastrointestinal Cancers Symposium
Feasibility and value of incorporating pharmacogenomic testing for genetic variants in UGT1A1 and DPYD genes in patients receiving irinotecan and/or 5-fluorouracil chemotherapy.
Authors
Candice Baldeo
Mayo Clinic, Jacksonville, FL
Candice Baldeo , Caren Hughes , Pashtoon Murtaza Kasi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 814)
DOI
10.1200/JCO.2018.36.4_suppl.814
Abstract #
814
Poster Bd #
M13
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
Identifying the importance of integrating routine pharmacogenomic testing for UGT1A1 and DPYD/tyms genetic variants in patients receiving irinotecan and/or 5-fluorouracil chemotherapy.
First Author: Candice Baldeo
Poster
2015 ASCO Annual Meeting
DPYD c.1905+1G>A and c.2846A>T and UGT1A1*28 allelic variants as predictors of toxicity: Pharmacogenetic translational analysis from the phase III TRIBE study in metastatic colorectal cancer.
First Author: Marzia Del Re
Poster
2020 ASCO Virtual Scientific Program
Prophylactic dihydropyrimidine dehydrogenase (DPYD), and reactive cytidine deaminase (CDA) testing is feasible and reduces severe toxicity in Irish patients receiving 5-fluorouracil (5-FU) based chemotherapy.
First Author: Jake Murphy
Poster
2016 Gastrointestinal Cancers Symposium
Novel drug discovery by pharmacogenomic profiling of 36 colorectal cancer cell lines.
First Author: Peter Eide